世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

バイオ分析検査サービス市場：タイプ、アプリケーション（腫瘍、神経、感染症、消化器、循環器）、エンドユーザー、地域（北米、欧州、APAC、中南米、MEA）別-2027年までの世界予測


Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) - Global Forecast to 2027

バイオ分析試験には、生物学的およびバイオテクノロジー製品の詳細な検査に使用される分析方法が含まれます。バイオ分析では、薬物やその代謝物、不自然な位置や濃度の生体分子、DNA、巨大分子などを定量的に測定... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年6月6日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		203 190 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

バイオ分析試験には、生物学的およびバイオテクノロジー製品の詳細な検査に使用される分析方法が含まれます。バイオ分析では、薬物やその代謝物、不自然な位置や濃度の生体分子、DNA、巨大分子などを定量的に測定することができます。バイオ分析試験サービスの世界市場は、2022年の推定29億米ドルから2027年には60億米ドルに達し、予測期間中に15.6%のCAGRで推移すると予測されています。

"セルベースアッセイセグメントがバイオ分析テストサービス市場で最大のシェアを占める見込み"
慢性疾患の増加や臨床試験数の増加が、セルベースアッセイ市場の成長を支えるものと予想されます。セルベースアッセイは、さまざまな試薬や細胞を用いて、細胞のメカニズムや機能を定量的・定性的に評価するために用いられる試験管内アッセイです。これらのアッセイは、自然条件下における細胞の特性を研究するために使用されます。

"バイオアナリティカルテスティングサービス市場において、オンコロジーセグメントが最大のシェアを占めると予想される"
2021年の世界のバイオ分析テストサービス市場では、オンコロジーセグメントが最大のシェアを占めています。世界的な医療制度におけるがんの負担の増加に伴い、政府機関と民間機関の両方が、新規のがん治療法の開発にますます力を入れるようになっています。このため、抗がん剤の臨床試験におけるバイオ分析試験サービスの需要が高まると予想されます。ICON社（アイルランド）、Syneos Health社（米国）、PAREXEL International社（米国）などが、抗がん剤の臨床試験向けのサービスを提供する大手企業です。

"バイオ分析試験サービス市場では、製薬・バイオ製薬会社セグメントが最大のシェアを占めると予想される"
2021年のバイオ分析試験サービス世界市場では、製薬・バイオ製薬会社セグメントが最大のシェアを占めています。製薬・バイオ製薬会社は主に、様々な病気の治療のための新薬の開発に注力しています。これらの企業は、医薬品開発プロセスおよびその後の規制機関への申請において、医薬品開発に関連する特定のデータを提出する必要があります。このため、規制要件を満たすために、開発の初期段階や臨床段階において幅広いサービスが必要となります。

"予測期間中に最も高い成長を遂げるのはアジア太平洋地域市場"
APAC市場は、予測期間中に最も高いCAGRで成長すると推定されます。これは主に、製薬およびバイオ医薬品業界の急成長、臨床試験の低コスト化、この地域のいくつかの国における有利な政府政策に起因するものです。

本レポートで参照した生物学的分析試験サービス市場の主要参加者の内訳は以下の通りである。
- 企業タイプ別企業タイプ別：Tier 1-35%、Tier 2-45%、Tier 3-20
- 役職別Cレベル-30%, ディレクターレベル-55%, その他-15
- 地域別北米-40％、欧州-25％、アジア太平洋-20％、中南米-10％、中東・アフリカ-5％。

生物学的分析試験サービス市場の有力企業には、Charles River（米国）、Medpace（米国）、WuXi AppTec（中国）、Eurofins Scientific（ルクセンブルク）、IQVIA（米国）、SGS SA（スイス）、Laboratory Corporation of America Holdings（米国）、Intertek Group（英国）、Synos Health（米国）、ICON（アイルランド）、Frontage Labs（米国）、PPD（米国）、が含まれています。PAREXEL International Corporation（米国）、Almac Group（英国）、Celerion（米国）、Altasciences（米国）、BioAgilytix Labs（米国）、Lotus Labs（インド）、LGS Limited（英国）、Sartorius AG（ドイツ）、CD BioSciences（米国）、Absorption Systems LLC（米国）、Pace Analytical Services（米国）、Bioneeds India Private Limited（インド）および Vipragen Biosciences（インド）です。
調査対象範囲
本レポートでは、様々なバイオ分析試験サービスの市場とその採用パターンを分析しています。世界のバイオ分析検査サービス市場とタイプ、アプリケーション、エンドユーザー、地域などの異なるセグメントの市場規模および将来の成長可能性を推定することを目的としています。また、同市場の主要企業の企業概要、製品・サービス内容、最近の動向とともに、詳細な競合分析も掲載しています。

本レポートを購入する理由
本レポートは、既存企業だけでなく、新規参入企業や中小企業も市場の脈拍を測ることができ、ひいてはより大きなシェアを獲得するのに役立つでしょう。本レポートを購入された企業は、以下の5つの戦略を組み合わせることで、市場での存在感を高めることができます。

本レポートでは、以下のポイントについて考察しています。
- 市場浸透。生物学的分析試験サービスの世界市場でトップ企業が提供する製品ポートフォリオに関する包括的な情報
- 製品開発/イノベーション。生物学的分析試験サービスの世界市場における今後の動向、研究開発活動、製品またはサービスの発売に関する詳細な洞察
- 市場開発。タイプ、アプリケーション、エンドユーザー、地域ごとの有利な新興地域に関する包括的な情報
- 市場の多様化。新製品、成長地域、生物学的分析試験サービスの世界市場における最近の開発に関する徹底的な情報。
- 競争力の評価。世界のバイオ分析試験サービス市場における主要企業の市場シェア、成長戦略、収益分析、製品・サービスに関する詳細な評価。

ページTOPに戻る


目次

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION & SCOPE 25
1.2.1 MARKETS COVERED 26
FIGURE 1 BIOANALYTICAL TESTING SERVICES MARKET SEGMENTATION 26
1.2.2 YEARS CONSIDERED FOR THE STUDY 26
1.3 CURRENCY 27
TABLE 1 STANDARD CURRENCY CONVERSION RATES 27
1.4 STAKEHOLDERS 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
FIGURE 2 RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 29
2.1.1.1 Key data from secondary sources 30
2.1.2 PRIMARY DATA 30
FIGURE 3 PRIMARY SOURCES 30
2.1.2.1 Key data from primary sources 31
2.1.2.2 Key industry insights 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 33
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 34
FIGURE 6 DATA TRIANGULATION METHODOLOGY 34
2.4 MARKET RANKING ANALYSIS 35
2.5 ASSUMPTIONS FOR THE STUDY 35
3 EXECUTIVE SUMMARY 36
FIGURE 7 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 36
FIGURE 8 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 37
FIGURE 9 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 37
FIGURE 10 BIOANALYTICAL TESTING SERVICES MARKET: REGIONAL SNAPSHOT 38
 
4 PREMIUM INSIGHTS 39
4.1 BIOANALYTICAL TESTING SERVICES MARKET OVERVIEW 39
FIGURE 11 RISING FOCUS ON ANALYTICAL TESTING OF BIOLOGICS AND
BIOSIMILARS TO DRIVE MARKET GROWTH 39
4.2 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION & COUNTRY (2021) 40
FIGURE 12 ONCOLOGY SEGMENT TO DOMINATE ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET IN 2021 40
4.3 BIOANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 41
FIGURE 13 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 41
4.4 REGIONAL MIX: BIOANALYTICAL TESTING SERVICES MARKET 42
FIGURE 14 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 42
4.5 BIOANALYTICAL TESTING SERVICES MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 42
FIGURE 15 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 16 BIOANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 DRIVERS 44
5.2.1.1 Rising focus on the analytical testing of biologics and biosimilars 44
TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS 44
5.2.1.2 Increasing preference for outsourcing analytical testing 44
5.2.1.3 Growing R&D expenditure in the pharmaceutical and biopharmaceutical industry 45
FIGURE 17 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE,
2017–2024 45
5.2.1.4 Rising adoption of the Quality by Design approach 45
5.2.2 RESTRAINTS 46
5.2.2.1 Dearth of skilled professionals 46
5.2.2.2 Pricing pressure faced by major players 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Emerging countries in the Asia Pacific region 46
5.2.3.2 Rising demand for specialized bioanalytical testing services 47
5.2.4 CHALLENGES 47
5.2.4.1 Innovative formulations demanding a unique bioanalytical testing approach 47
5.2.4.2 Growing need to improve the sensitivity of bioanalytical methods 48
5.3 ASSESSMENT OF COVID-19 IMPACT ON THE ECONOMIC SCENARIO IN THE BIOANALYTICAL TESTING SERVICES MARKET 48
 
6 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE 50
6.1 INTRODUCTION 51
TABLE 3 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 51
6.2 CELL-BASED ASSAYS 51
TABLE 4 BIOANALYTICAL TESTING SERVICES MARKET FOR CELL-BASED ASSAYS,
BY TYPE, 2020–2027 (USD MILLION) 52
TABLE 5 BIOANALYTICAL TESTING SERVICES MARKET FOR CELL-BASED ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 52
6.2.1 BACTERIAL CELL-BASED ASSAYS 53
6.2.1.1 Bacterial cell-based assays dominate the bioanalytical testing services market for cell-based assays 53
TABLE 6 BIOANALYTICAL TESTING SERVICES MARKET FOR BACTERIAL
CELL-BASED ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 53
6.2.2 VIRAL CELL-BASED ASSAYS 54
6.2.2.1 Increasing outbreaks of viral diseases to support the growth of this market segment 54
TABLE 7 BIOANALYTICAL TESTING SERVICES MARKET FOR VIRAL
CELL-BASED ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 54
6.3 VIROLOGY TESTING 55
TABLE 8 BIOANALYTICAL TESTING SERVICES MARKET FOR VIROLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION) 55
TABLE 9 BIOANALYTICAL TESTING SERVICES MARKET FOR VIROLOGY TESTING,
BY COUNTRY, 2020–2027 (USD MILLION) 56
6.3.1 IN VITRO VIROLOGY TESTING 56
6.3.1.1 Higher uptake of in vitro virology assays in the development of anti-viral pharmaceuticals to drive the growth of this market segment 56
TABLE 10 BIOANALYTICAL TESTING SERVICES MARKET FOR IN VITRO VIROLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 57
6.3.2 IN VIVO VIROLOGY TESTING 57
6.3.2.1 High utilization of in vivo assays during important production phases to drive their demand 57
TABLE 11 BIOANALYTICAL TESTING SERVICES MARKET FOR IN VIVO VIROLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 58
6.3.3 SPECIES-SPECIFIC VIRAL PCR ASSAYS 58
6.3.3.1 Wide application of species-specific viral PCR assays in the detection of viral risks to support the growth of this market segment 58
TABLE 12 BIOANALYTICAL TESTING SERVICES MARKET FOR SPECIES-SPECIFIC VIRAL PCR ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 59
6.4 METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION 59
6.4.1 MANDATORY REQUIREMENT BY REGULATORY AUTHORITIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 59
TABLE 13 BIOANALYTICAL TESTING SERVICES MARKET FOR METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION) 60
 
6.5 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES 61
6.5.1 INCREASING APPLICATIONS OF SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 61
TABLE 14 BIOANALYTICAL TESTING SERVICES MARKET FOR SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES, BY COUNTRY, 2020–2027 (USD MILLION) 62
6.6 BIOMARKER TESTING 62
6.6.1 GROWING EMPHASIS ON THE DEVELOPMENT OF PERSONALIZED MEDICINES TO DRIVE THE DEMAND FOR BIOMARKER TESTING SERVICES 62
TABLE 15 BIOANALYTICAL TESTING SERVICES MARKET FOR BIOMARKER TESTING,
BY COUNTRY, 2020–2027 (USD MILLION) 63
6.7 PHARMACOKINETIC TESTING 63
6.7.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE THE DEMAND FOR PHARMACOKINETIC TESTING SERVICES 63
TABLE 16 BIOANALYTICAL TESTING SERVICES MARKET FOR PHARMACOKINETIC TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 64
6.8 OTHER SERVICES 64
TABLE 17 BIOANALYTICAL TESTING SERVICES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2020–2027 (USD MILLION) 65
7 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION 66
7.1 INTRODUCTION 67
TABLE 18 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 67
7.2 ONCOLOGY 67
7.2.1 ONCOLOGY IS THE LARGEST APPLICATION SEGMENT IN THE BIOANALYTICAL TESTING SERVICES MARKET 67
FIGURE 18 WORLDWIDE CANCER INCIDENCE AND MORTALITY (2018–2040) 68
TABLE 19 BIOANALYTICAL TESTING SERVICES MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 69
7.3 NEUROLOGY 69
7.3.1 ROBUST PIPELINE OF DRUGS FOR CNS DISEASES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 69
TABLE 20 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 70
TABLE 21 BIOANALYTICAL TESTING SERVICES MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 71
7.4 INFECTIOUS DISEASES 71
7.4.1 OUTBREAK OF COVID-19 TO BOOST THE GROWTH OF THIS MARKET SEGMENT 71
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 72
7.5 GASTROENTEROLOGY 72
7.5.1 RISING PREVALENCE OF CHRONIC DIGESTIVE DISORDERS TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT 72
TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET FOR GASTROENTEROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 73
 
7.6 CARDIOLOGY 73
7.6.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT 73
TABLE 24 BIOANALYTICAL TESTING SERVICES MARKET FOR CARDIOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74
7.7 OTHER APPLICATIONS 74
TABLE 25 BIOANALYTICAL TESTING SERVICES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 75
8 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER 76
8.1 INTRODUCTION 77
TABLE 26 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 77
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 77
8.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ARE
THE LARGEST END USERS OF BIOANALYTICAL TESTING SERVICES 77
FIGURE 19 PHARMACEUTICAL R&D SPENDING, 2010–2024 78
TABLE 27 BIOANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 78
8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS 79
8.3.1 CDMOS PROVIDE SERVICES SUCH AS ANALYTICAL DEVELOPMENT, FORMULATION SCREENING AND DEVELOPMENT, STABILITY STUDIES,
AND PRE-CLINICAL SAFETY ASSESSMENT STUDIES 79
TABLE 28 BIOANALYTICAL TESTING SERVICES MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 80
8.4 CONTRACT RESEARCH ORGANIZATIONS 80
8.4.1 CONTRACT RESEARCH ORGANIZATIONS ARE INCREASINGLY SUBCONTRACTING THEIR ACTIVITIES TO NICHE LABORATORIES
SPECIALIZED IN PROVIDING BIOANALYTICAL TESTING SERVICES 80
TABLE 29 BIOANALYTICAL TESTING SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 81
9 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 82
9.1 INTRODUCTION 83
FIGURE 20 CHINA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD 83
TABLE 30 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 84
9.2 NORTH AMERICA 84
FIGURE 21 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET SNAPSHOT 85
TABLE 31 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 32 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 33 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 86
TABLE 34 NORTH AMERICA: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 87
TABLE 35 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 87
TABLE 36 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2020–2027 (USD MILLION) 87
9.2.1 US 88
9.2.1.1 US is largest market for bioanalytical testing services
in North America 88
TABLE 37 US: KEY INDICATORS 88
TABLE 38 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 89
TABLE 39 US: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 40 US: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 41 US: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 90
TABLE 42 US: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 90
9.2.2 CANADA 91
9.2.2.1 Increasing number of clinical trials in Canada to
support market growth 91
TABLE 43 CANADA: KEY INDICATORS: 91
TABLE 44 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 92
TABLE 45 CANADA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 92
TABLE 46 CANADA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 47 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93
TABLE 48 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 93
9.3 EUROPE 93
TABLE 49 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 94
TABLE 50 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 95
TABLE 51 EUROPE: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 95
TABLE 52 EUROPE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 53 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
TABLE 54 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 96
9.3.1 GERMANY 96
9.3.1.1 Government support and flexible labor laws have made
Germany a favorable location for clinical trials 96
TABLE 55 GERMANY: KEY INDICATORS 97
TABLE 56 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 97
TABLE 57 GERMANY: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 58 GERMANY: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 59 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
TABLE 60 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.3.2 FRANCE 99
9.3.2.1 High number of oncology clinical trials in France to drive
market growth 99
TABLE 61 FRANCE: KEY INDICATORS 100
TABLE 62 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 63 FRANCE: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 64 FRANCE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 101
TABLE 65 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
TABLE 66 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 101
9.3.3 UK 102
9.3.3.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth 102
TABLE 67 UK: KEY INDICATORS 102
TABLE 68 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 102
TABLE 69 UK: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 70 UK: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 71 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 103
TABLE 72 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 104
9.3.4 ITALY 104
9.3.4.1 Low drug approval time in Italy, along with the growing number of clinical trials, to drive market growth 104
TABLE 73 ITALY: KEY INDICATORS 104
TABLE 74 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 105
TABLE 75 ITALY: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 76 ITALY: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 77 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 106
TABLE 78 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 106
9.3.5 SPAIN 107
9.3.5.1 Rising R&D expenditure to boost market growth 107
TABLE 79 SPAIN: KEY INDICATORS 107
TABLE 80 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 108
TABLE 81 SPAIN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 82 SPAIN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 83 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 109
TABLE 84 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 109
9.3.6 REST OF EUROPE 109
TABLE 85 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 110
TABLE 86 ROE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 87 ROE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 88 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 111
TABLE 89 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 112
9.4 ASIA PACIFIC 112
FIGURE 22 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET SNAPSHOT 113
TABLE 90 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 91 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 92 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 93 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 115
TABLE 94 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115
TABLE 95 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 115
9.4.1 CHINA 116
9.4.1.1 China is largest market for bioanalytical testing services in
Asia Pacific 116
TABLE 96 CHINA: KEY INDICATORS 116
TABLE 97 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 117
TABLE 98 CHINA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 99 CHINA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 100 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 118
TABLE 101 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 118
9.4.2 JAPAN 118
9.4.2.1 Rising geriatric population to drive market growth in Japan 118
TABLE 102 JAPAN: KEY INDICATORS 119
TABLE 103 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 104 JAPAN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 105 JAPAN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 106 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 120
TABLE 107 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 121
9.4.3 INDIA 121
9.4.3.1 Growing pharmaceutical industry in India to drive market growth 121
TABLE 108 INDIA: KEY INDICATORS 122
TABLE 109 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 122
TABLE 110 INDIA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 111 INDIA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 112 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 123
TABLE 113 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 123
9.4.4 REST OF ASIA PACIFIC 124
TABLE 114 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 124
TABLE 115 ROAPAC: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 125
TABLE 116 ROAPAC: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 117 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
TABLE 118 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 126
9.5 LATIN AMERICA 126
9.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH 126
TABLE 119 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 120 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 121 LATIN AMERICA: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 128
TABLE 122 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 123 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 128
 
9.6 MIDDLE EAST & AFRICA 129
9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH 129
TABLE 124 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 125 MIDDLE EAST & AFRICA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 126 MIDDLE EAST & AFRICA: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 127 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 128 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2020–2027 (USD MILLION) 131
10 COMPETITIVE LANDSCAPE 132
10.1 INTRODUCTION 132
FIGURE 23 KEY DEVELOPMENTS IN BIOANALYTICAL TESTING SERVICES MARKET 132
10.2 COMPETITIVE LEADERSHIP MAPPING 133
10.2.1 STARS 133
10.2.2 EMERGING LEADERS 133
10.2.3 PERVASIVE PLAYERS 133
10.2.4 PARTICIPANTS 133
FIGURE 24 BIOANALYTICAL TESTING SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 134
10.3 BIOANALYTICAL TESTING SERVICES MARKET SHARE ANALYSIS 134
FIGURE 25 MARKET SHARE ANALYSIS: BIOANALYTICAL
TESTING SERVICES MARKET (2021) 135
10.4 BIOANALYTICAL TESTING SERVICES MARKET: GEOGRAPHICAL ASSESSMENT 136
FIGURE 26 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN BIOANALYTICAL TESTING SERVICES MARKET (2021) 136
10.5 COMPETITIVE SITUATIONS & TRENDS 137
10.5.1 PRODUCT LAUNCHES (2020–2022) 137
10.5.2 EXPANSIONS (2020–2022) 137
10.5.3 DEALS (2020–2022) 138
11 COMPANY PROFILES 139
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 CHARLES RIVER 139
TABLE 129 CHARLES RIVER: BUSINESS OVERVIEW 139
FIGURE 27 CHARLES RIVER: COMPANY SNAPSHOT (2021) 140
11.2 MEDPACE HOLDINGS 146
TABLE 130 MEDPACE HOLDINGS: BUSINESS OVERVIEW 146
FIGURE 28 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2021) 146
 
11.3 WUXI APPTEC 149
TABLE 131 WUXI APPTEC: BUSINESS OVERVIEW 149
FIGURE 29 WUXI APPTEC: COMPANY SNAPSHOT (2021) 150
11.4 EUROFINS SCIENTIFIC 153
TABLE 132 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 153
FIGURE 30 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 154
11.5 IQVIA INC. 157
TABLE 133 IQVIA: BUSINESS OVERVIEW 157
FIGURE 31 IQVIA: COMPANY SNAPSHOT (2021) 158
11.6 SGS SA 161
TABLE 134 SGS SA: BUSINESS OVERVIEW 161
FIGURE 32 SGS SA: COMPANY SNAPSHOT (2021) 162
11.7 LABORATORY CORPORATION OF AMERICA HOLDINGS 165
TABLE 135 LABCORP: BUSINESS OVERVIEW 165
FIGURE 33 LABCORP: COMPANY SNAPSHOT (2021) 166
11.8 INTERTEK GROUP PLC 169
TABLE 136 INTERTEK GROUP PLC: BUSINESS OVERVIEW 169
FIGURE 34 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021) 170
11.9 SYNEOS HEALTH 172
TABLE 137 SYNEOS HEALTH: BUSINESS OVERVIEW 172
FIGURE 35 SYNEOS HEALTH: COMPANY SNAPSHOT (2021) 173
11.10 ICON PLC 175
TABLE 138 ICON: BUSINESS OVERVIEW 175
FIGURE 36 ICON: COMPANY SNAPSHOT (2021) 175
11.11 FRONTAGE LABS 178
TABLE 139 FRONTAGE LABS: BUSINESS OVERVIEW 178
FIGURE 37 FRONTAGE LABS: COMPANY SNAPSHOT (2021) 179
11.12 PPD, INC. 182
TABLE 140 PPD, INC: BUSINESS OVERVIEW 182
11.13 PAREXEL INTERNATIONAL CORPORATION 185
TABLE 141 PARAXEL INTERNATIONAL: BUSINESS OVERVIEW 185
11.14 ALMAC GROUP 187
TABLE 142 ALMAC GROUP: BUSINESS OVERVIEW 187
11.15 CELERION 189
TABLE 143 CELERION: BUSINESS OVERVIEW 189
11.16 ALTASCIENCES 190
TABLE 144 ALTASCIENCES: BUSINESS OVERVIEW 190
11.17 BIOAGILYTIX LABS 191
TABLE 145 BIOAGILYTIX: BUSINESS OVERVIEW 191
11.18 LOTUS LABS PVT. LTD. 192
TABLE 146 LOTUS LABS: BUSINESS OVERVIEW 192
 
11.19 LGC LIMITED 193
TABLE 147 LGC LIMITED: BUSINESS OVERVIEW 193
11.20 SARTORIUS AG 195
TABLE 148 SARTORIUS AG: BUSINESS OVERVIEW 195
11.21 CD BIOSCIENCES INC 196
TABLE 149 CD BIOSCIENCES INC: BUSINESS OVERVIEW 196
11.22 ABSORPTION SYSTEMS LLC 197
TABLE 150 ABSORPTION SYSTEMS LLC: BUSINESS OVERVIEW 197
11.23 PACE ANALYTICAL 198
TABLE 151 PACE ANALYTICAL: BUSINESS OVERVIEW 198
11.24 BIONEEDS INDIA PRIVATE LIMITED 199
TABLE 152 BIONEEDS INDIA PRIVATE LIMITED: BUSINESS OVERVIEW 199
11.25 VIPRAGEN BIOSCIENCES 200
TABLE 153 VIPRAGEN BIOSCIENCES: BUSINESS OVERVIEW 200
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 201
12.1 DISCUSSION GUIDE 201
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 204
12.3 AVAILABLE CUSTOMIZATIONS 206
12.4 RELATED REPORTS 207
12.5 AUTHOR DETAILS 208

　

ページTOPに戻る


　

Summary

Bioanalytical testing involves analytical methods used for the detailed examination of biological and biotechnology products. Bioanalysis enables the quantitative measurement of drugs and their metabolites, biological molecules in unnatural locations or concentrations, DNA, and large molecules. The global bioanalytical testing services market is projected to reach USD 6.0 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 15.6% during the forecast period.

“The Cell-based assays segment is expected to account for the largest share of the bioanalytical testing services market”
The increasing prevalence of chronic diseases and the rising number of clinical trials are expected to support the growth of the cell-based assays market. Cell-based assays are in vitro assays used for the quantitative and qualitative assessment of cellular mechanisms and functions using a wide range of reagents and cells. These assays are used to study the characteristics of a cell in natural conditions.

“The the oncology segment is expected to account for the largest share of the bioanalytical testing services market”
The oncology segment accounted for the largest share of the global bioanalytical testing services market in 2021. With the increasing burden of cancer on healthcare systems worldwide, both government and private organizations are increasingly focusing on developing novel cancer therapies. This is expected to drive the demand for bioanalytical testing services in the clinical trials of cancer drugs. ICON (Ireland), Syneos Health (US), and PAREXEL International (US) are the leading players offering services for the clinical trials of oncology drugs.

“The pharmaceutical and biopharmaceutical companies segment is expected to account for the largest share of the bioanalytical testing services market”
The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the global bioanalytical testing services market in 2021. Pharmaceutical and biopharmaceutical companies mainly focus on developing new drugs for the treatment of various diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements.

“Asia Pacific market to witness the highest growth during the forecast period”
The APAC market is estimated to grow at the highest CAGR during the forecast period. This is majorly attributed to the rapid growth in the pharmaceutical and biopharmaceutical industries, low cost of clinical trials, and favorable government policies in several countries in this region.

A breakdown of the primary participants for the bioanalytical testing services market referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation: C-level–30%, Director Level–55%, and Others–15%
• By Region: North America–40%, Europe–25%, Asia Pacific–20%, Latin America- 10%, Middle East & Africa-5%

The prominent players in the bioanalytical testing services market include Charles River (US), Medpace (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), IQVIA (US), SGS SA (Switzerland), Laboratory Corporation of America Holdings (US), Intertek Group (UK), Syneos Health (US), ICON (Ireland), Frontage Labs (US), PPD (US), PAREXEL International Corporation (US), Almac Group (UK), Celerion (US), Altasciences (US), BioAgilytix Labs (US), Lotus Labs (India), LGS Limited (UK), Sartorius AG (Germany), CD BioSciences (US), Absorption Systems LLC (US), Pace Analytical Services (US), Bioneeds India Private Limited (India) and Vipragen Biosciences (India).
Research Coverage:
The report analyzes the market for various bioanalytical testing services and their adoption pattern. It aims at estimating the market size and future growth potential of the global bioanalytical testing services market and different segments such as type, application, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global bioanalytical testing services market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global bioanalytical testing services market
• Market Development: Comprehensive information on the lucrative emerging regions by type, application, end user, and region
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global bioanalytical testing services market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global bioanalytical testing services market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION & SCOPE 25
1.2.1 MARKETS COVERED 26
FIGURE 1 BIOANALYTICAL TESTING SERVICES MARKET SEGMENTATION 26
1.2.2 YEARS CONSIDERED FOR THE STUDY 26
1.3 CURRENCY 27
TABLE 1 STANDARD CURRENCY CONVERSION RATES 27
1.4 STAKEHOLDERS 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
FIGURE 2 RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 29
2.1.1.1 Key data from secondary sources 30
2.1.2 PRIMARY DATA 30
FIGURE 3 PRIMARY SOURCES 30
2.1.2.1 Key data from primary sources 31
2.1.2.2 Key industry insights 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 33
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 34
FIGURE 6 DATA TRIANGULATION METHODOLOGY 34
2.4 MARKET RANKING ANALYSIS 35
2.5 ASSUMPTIONS FOR THE STUDY 35
3 EXECUTIVE SUMMARY 36
FIGURE 7 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 36
FIGURE 8 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 37
FIGURE 9 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 37
FIGURE 10 BIOANALYTICAL TESTING SERVICES MARKET: REGIONAL SNAPSHOT 38
 
4 PREMIUM INSIGHTS 39
4.1 BIOANALYTICAL TESTING SERVICES MARKET OVERVIEW 39
FIGURE 11 RISING FOCUS ON ANALYTICAL TESTING OF BIOLOGICS AND
BIOSIMILARS TO DRIVE MARKET GROWTH 39
4.2 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION & COUNTRY (2021) 40
FIGURE 12 ONCOLOGY SEGMENT TO DOMINATE ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET IN 2021 40
4.3 BIOANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 41
FIGURE 13 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 41
4.4 REGIONAL MIX: BIOANALYTICAL TESTING SERVICES MARKET 42
FIGURE 14 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 42
4.5 BIOANALYTICAL TESTING SERVICES MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 42
FIGURE 15 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 16 BIOANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 DRIVERS 44
5.2.1.1 Rising focus on the analytical testing of biologics and biosimilars 44
TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS 44
5.2.1.2 Increasing preference for outsourcing analytical testing 44
5.2.1.3 Growing R&D expenditure in the pharmaceutical and biopharmaceutical industry 45
FIGURE 17 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE,
2017–2024 45
5.2.1.4 Rising adoption of the Quality by Design approach 45
5.2.2 RESTRAINTS 46
5.2.2.1 Dearth of skilled professionals 46
5.2.2.2 Pricing pressure faced by major players 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Emerging countries in the Asia Pacific region 46
5.2.3.2 Rising demand for specialized bioanalytical testing services 47
5.2.4 CHALLENGES 47
5.2.4.1 Innovative formulations demanding a unique bioanalytical testing approach 47
5.2.4.2 Growing need to improve the sensitivity of bioanalytical methods 48
5.3 ASSESSMENT OF COVID-19 IMPACT ON THE ECONOMIC SCENARIO IN THE BIOANALYTICAL TESTING SERVICES MARKET 48
 
6 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE 50
6.1 INTRODUCTION 51
TABLE 3 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 51
6.2 CELL-BASED ASSAYS 51
TABLE 4 BIOANALYTICAL TESTING SERVICES MARKET FOR CELL-BASED ASSAYS,
BY TYPE, 2020–2027 (USD MILLION) 52
TABLE 5 BIOANALYTICAL TESTING SERVICES MARKET FOR CELL-BASED ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 52
6.2.1 BACTERIAL CELL-BASED ASSAYS 53
6.2.1.1 Bacterial cell-based assays dominate the bioanalytical testing services market for cell-based assays 53
TABLE 6 BIOANALYTICAL TESTING SERVICES MARKET FOR BACTERIAL
CELL-BASED ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 53
6.2.2 VIRAL CELL-BASED ASSAYS 54
6.2.2.1 Increasing outbreaks of viral diseases to support the growth of this market segment 54
TABLE 7 BIOANALYTICAL TESTING SERVICES MARKET FOR VIRAL
CELL-BASED ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 54
6.3 VIROLOGY TESTING 55
TABLE 8 BIOANALYTICAL TESTING SERVICES MARKET FOR VIROLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION) 55
TABLE 9 BIOANALYTICAL TESTING SERVICES MARKET FOR VIROLOGY TESTING,
BY COUNTRY, 2020–2027 (USD MILLION) 56
6.3.1 IN VITRO VIROLOGY TESTING 56
6.3.1.1 Higher uptake of in vitro virology assays in the development of anti-viral pharmaceuticals to drive the growth of this market segment 56
TABLE 10 BIOANALYTICAL TESTING SERVICES MARKET FOR IN VITRO VIROLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 57
6.3.2 IN VIVO VIROLOGY TESTING 57
6.3.2.1 High utilization of in vivo assays during important production phases to drive their demand 57
TABLE 11 BIOANALYTICAL TESTING SERVICES MARKET FOR IN VIVO VIROLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 58
6.3.3 SPECIES-SPECIFIC VIRAL PCR ASSAYS 58
6.3.3.1 Wide application of species-specific viral PCR assays in the detection of viral risks to support the growth of this market segment 58
TABLE 12 BIOANALYTICAL TESTING SERVICES MARKET FOR SPECIES-SPECIFIC VIRAL PCR ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 59
6.4 METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION 59
6.4.1 MANDATORY REQUIREMENT BY REGULATORY AUTHORITIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 59
TABLE 13 BIOANALYTICAL TESTING SERVICES MARKET FOR METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION) 60
 
6.5 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES 61
6.5.1 INCREASING APPLICATIONS OF SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 61
TABLE 14 BIOANALYTICAL TESTING SERVICES MARKET FOR SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES, BY COUNTRY, 2020–2027 (USD MILLION) 62
6.6 BIOMARKER TESTING 62
6.6.1 GROWING EMPHASIS ON THE DEVELOPMENT OF PERSONALIZED MEDICINES TO DRIVE THE DEMAND FOR BIOMARKER TESTING SERVICES 62
TABLE 15 BIOANALYTICAL TESTING SERVICES MARKET FOR BIOMARKER TESTING,
BY COUNTRY, 2020–2027 (USD MILLION) 63
6.7 PHARMACOKINETIC TESTING 63
6.7.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE THE DEMAND FOR PHARMACOKINETIC TESTING SERVICES 63
TABLE 16 BIOANALYTICAL TESTING SERVICES MARKET FOR PHARMACOKINETIC TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 64
6.8 OTHER SERVICES 64
TABLE 17 BIOANALYTICAL TESTING SERVICES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2020–2027 (USD MILLION) 65
7 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION 66
7.1 INTRODUCTION 67
TABLE 18 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 67
7.2 ONCOLOGY 67
7.2.1 ONCOLOGY IS THE LARGEST APPLICATION SEGMENT IN THE BIOANALYTICAL TESTING SERVICES MARKET 67
FIGURE 18 WORLDWIDE CANCER INCIDENCE AND MORTALITY (2018–2040) 68
TABLE 19 BIOANALYTICAL TESTING SERVICES MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 69
7.3 NEUROLOGY 69
7.3.1 ROBUST PIPELINE OF DRUGS FOR CNS DISEASES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 69
TABLE 20 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 70
TABLE 21 BIOANALYTICAL TESTING SERVICES MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 71
7.4 INFECTIOUS DISEASES 71
7.4.1 OUTBREAK OF COVID-19 TO BOOST THE GROWTH OF THIS MARKET SEGMENT 71
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 72
7.5 GASTROENTEROLOGY 72
7.5.1 RISING PREVALENCE OF CHRONIC DIGESTIVE DISORDERS TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT 72
TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET FOR GASTROENTEROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 73
 
7.6 CARDIOLOGY 73
7.6.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT 73
TABLE 24 BIOANALYTICAL TESTING SERVICES MARKET FOR CARDIOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74
7.7 OTHER APPLICATIONS 74
TABLE 25 BIOANALYTICAL TESTING SERVICES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 75
8 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER 76
8.1 INTRODUCTION 77
TABLE 26 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 77
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 77
8.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ARE
THE LARGEST END USERS OF BIOANALYTICAL TESTING SERVICES 77
FIGURE 19 PHARMACEUTICAL R&D SPENDING, 2010–2024 78
TABLE 27 BIOANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 78
8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS 79
8.3.1 CDMOS PROVIDE SERVICES SUCH AS ANALYTICAL DEVELOPMENT, FORMULATION SCREENING AND DEVELOPMENT, STABILITY STUDIES,
AND PRE-CLINICAL SAFETY ASSESSMENT STUDIES 79
TABLE 28 BIOANALYTICAL TESTING SERVICES MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 80
8.4 CONTRACT RESEARCH ORGANIZATIONS 80
8.4.1 CONTRACT RESEARCH ORGANIZATIONS ARE INCREASINGLY SUBCONTRACTING THEIR ACTIVITIES TO NICHE LABORATORIES
SPECIALIZED IN PROVIDING BIOANALYTICAL TESTING SERVICES 80
TABLE 29 BIOANALYTICAL TESTING SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 81
9 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 82
9.1 INTRODUCTION 83
FIGURE 20 CHINA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD 83
TABLE 30 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 84
9.2 NORTH AMERICA 84
FIGURE 21 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET SNAPSHOT 85
TABLE 31 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 32 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 33 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 86
TABLE 34 NORTH AMERICA: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 87
TABLE 35 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 87
TABLE 36 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2020–2027 (USD MILLION) 87
9.2.1 US 88
9.2.1.1 US is largest market for bioanalytical testing services
in North America 88
TABLE 37 US: KEY INDICATORS 88
TABLE 38 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 89
TABLE 39 US: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 40 US: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 41 US: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 90
TABLE 42 US: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 90
9.2.2 CANADA 91
9.2.2.1 Increasing number of clinical trials in Canada to
support market growth 91
TABLE 43 CANADA: KEY INDICATORS: 91
TABLE 44 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 92
TABLE 45 CANADA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 92
TABLE 46 CANADA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 47 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93
TABLE 48 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 93
9.3 EUROPE 93
TABLE 49 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 94
TABLE 50 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 95
TABLE 51 EUROPE: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 95
TABLE 52 EUROPE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 53 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
TABLE 54 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 96
9.3.1 GERMANY 96
9.3.1.1 Government support and flexible labor laws have made
Germany a favorable location for clinical trials 96
TABLE 55 GERMANY: KEY INDICATORS 97
TABLE 56 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 97
TABLE 57 GERMANY: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 58 GERMANY: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 59 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
TABLE 60 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.3.2 FRANCE 99
9.3.2.1 High number of oncology clinical trials in France to drive
market growth 99
TABLE 61 FRANCE: KEY INDICATORS 100
TABLE 62 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 63 FRANCE: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 64 FRANCE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 101
TABLE 65 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
TABLE 66 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 101
9.3.3 UK 102
9.3.3.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth 102
TABLE 67 UK: KEY INDICATORS 102
TABLE 68 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 102
TABLE 69 UK: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 70 UK: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 71 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 103
TABLE 72 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 104
9.3.4 ITALY 104
9.3.4.1 Low drug approval time in Italy, along with the growing number of clinical trials, to drive market growth 104
TABLE 73 ITALY: KEY INDICATORS 104
TABLE 74 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 105
TABLE 75 ITALY: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 76 ITALY: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 77 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 106
TABLE 78 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 106
9.3.5 SPAIN 107
9.3.5.1 Rising R&D expenditure to boost market growth 107
TABLE 79 SPAIN: KEY INDICATORS 107
TABLE 80 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 108
TABLE 81 SPAIN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 82 SPAIN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 83 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 109
TABLE 84 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 109
9.3.6 REST OF EUROPE 109
TABLE 85 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 110
TABLE 86 ROE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 87 ROE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 88 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 111
TABLE 89 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 112
9.4 ASIA PACIFIC 112
FIGURE 22 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET SNAPSHOT 113
TABLE 90 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 91 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 92 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 93 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 115
TABLE 94 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115
TABLE 95 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 115
9.4.1 CHINA 116
9.4.1.1 China is largest market for bioanalytical testing services in
Asia Pacific 116
TABLE 96 CHINA: KEY INDICATORS 116
TABLE 97 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 117
TABLE 98 CHINA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 99 CHINA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 100 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 118
TABLE 101 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 118
9.4.2 JAPAN 118
9.4.2.1 Rising geriatric population to drive market growth in Japan 118
TABLE 102 JAPAN: KEY INDICATORS 119
TABLE 103 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 104 JAPAN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 105 JAPAN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 106 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 120
TABLE 107 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 121
9.4.3 INDIA 121
9.4.3.1 Growing pharmaceutical industry in India to drive market growth 121
TABLE 108 INDIA: KEY INDICATORS 122
TABLE 109 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 122
TABLE 110 INDIA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 111 INDIA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 112 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 123
TABLE 113 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 123
9.4.4 REST OF ASIA PACIFIC 124
TABLE 114 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 124
TABLE 115 ROAPAC: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 125
TABLE 116 ROAPAC: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 117 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
TABLE 118 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER,
2020–2027 (USD MILLION) 126
9.5 LATIN AMERICA 126
9.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH 126
TABLE 119 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 120 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 121 LATIN AMERICA: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 128
TABLE 122 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 123 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 128
 
9.6 MIDDLE EAST & AFRICA 129
9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH 129
TABLE 124 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 125 MIDDLE EAST & AFRICA: CELL-BASED ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 126 MIDDLE EAST & AFRICA: VIROLOGY TESTING MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 127 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 128 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2020–2027 (USD MILLION) 131
10 COMPETITIVE LANDSCAPE 132
10.1 INTRODUCTION 132
FIGURE 23 KEY DEVELOPMENTS IN BIOANALYTICAL TESTING SERVICES MARKET 132
10.2 COMPETITIVE LEADERSHIP MAPPING 133
10.2.1 STARS 133
10.2.2 EMERGING LEADERS 133
10.2.3 PERVASIVE PLAYERS 133
10.2.4 PARTICIPANTS 133
FIGURE 24 BIOANALYTICAL TESTING SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 134
10.3 BIOANALYTICAL TESTING SERVICES MARKET SHARE ANALYSIS 134
FIGURE 25 MARKET SHARE ANALYSIS: BIOANALYTICAL
TESTING SERVICES MARKET (2021) 135
10.4 BIOANALYTICAL TESTING SERVICES MARKET: GEOGRAPHICAL ASSESSMENT 136
FIGURE 26 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN BIOANALYTICAL TESTING SERVICES MARKET (2021) 136
10.5 COMPETITIVE SITUATIONS & TRENDS 137
10.5.1 PRODUCT LAUNCHES (2020–2022) 137
10.5.2 EXPANSIONS (2020–2022) 137
10.5.3 DEALS (2020–2022) 138
11 COMPANY PROFILES 139
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 CHARLES RIVER 139
TABLE 129 CHARLES RIVER: BUSINESS OVERVIEW 139
FIGURE 27 CHARLES RIVER: COMPANY SNAPSHOT (2021) 140
11.2 MEDPACE HOLDINGS 146
TABLE 130 MEDPACE HOLDINGS: BUSINESS OVERVIEW 146
FIGURE 28 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2021) 146
 
11.3 WUXI APPTEC 149
TABLE 131 WUXI APPTEC: BUSINESS OVERVIEW 149
FIGURE 29 WUXI APPTEC: COMPANY SNAPSHOT (2021) 150
11.4 EUROFINS SCIENTIFIC 153
TABLE 132 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 153
FIGURE 30 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 154
11.5 IQVIA INC. 157
TABLE 133 IQVIA: BUSINESS OVERVIEW 157
FIGURE 31 IQVIA: COMPANY SNAPSHOT (2021) 158
11.6 SGS SA 161
TABLE 134 SGS SA: BUSINESS OVERVIEW 161
FIGURE 32 SGS SA: COMPANY SNAPSHOT (2021) 162
11.7 LABORATORY CORPORATION OF AMERICA HOLDINGS 165
TABLE 135 LABCORP: BUSINESS OVERVIEW 165
FIGURE 33 LABCORP: COMPANY SNAPSHOT (2021) 166
11.8 INTERTEK GROUP PLC 169
TABLE 136 INTERTEK GROUP PLC: BUSINESS OVERVIEW 169
FIGURE 34 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021) 170
11.9 SYNEOS HEALTH 172
TABLE 137 SYNEOS HEALTH: BUSINESS OVERVIEW 172
FIGURE 35 SYNEOS HEALTH: COMPANY SNAPSHOT (2021) 173
11.10 ICON PLC 175
TABLE 138 ICON: BUSINESS OVERVIEW 175
FIGURE 36 ICON: COMPANY SNAPSHOT (2021) 175
11.11 FRONTAGE LABS 178
TABLE 139 FRONTAGE LABS: BUSINESS OVERVIEW 178
FIGURE 37 FRONTAGE LABS: COMPANY SNAPSHOT (2021) 179
11.12 PPD, INC. 182
TABLE 140 PPD, INC: BUSINESS OVERVIEW 182
11.13 PAREXEL INTERNATIONAL CORPORATION 185
TABLE 141 PARAXEL INTERNATIONAL: BUSINESS OVERVIEW 185
11.14 ALMAC GROUP 187
TABLE 142 ALMAC GROUP: BUSINESS OVERVIEW 187
11.15 CELERION 189
TABLE 143 CELERION: BUSINESS OVERVIEW 189
11.16 ALTASCIENCES 190
TABLE 144 ALTASCIENCES: BUSINESS OVERVIEW 190
11.17 BIOAGILYTIX LABS 191
TABLE 145 BIOAGILYTIX: BUSINESS OVERVIEW 191
11.18 LOTUS LABS PVT. LTD. 192
TABLE 146 LOTUS LABS: BUSINESS OVERVIEW 192
 
11.19 LGC LIMITED 193
TABLE 147 LGC LIMITED: BUSINESS OVERVIEW 193
11.20 SARTORIUS AG 195
TABLE 148 SARTORIUS AG: BUSINESS OVERVIEW 195
11.21 CD BIOSCIENCES INC 196
TABLE 149 CD BIOSCIENCES INC: BUSINESS OVERVIEW 196
11.22 ABSORPTION SYSTEMS LLC 197
TABLE 150 ABSORPTION SYSTEMS LLC: BUSINESS OVERVIEW 197
11.23 PACE ANALYTICAL 198
TABLE 151 PACE ANALYTICAL: BUSINESS OVERVIEW 198
11.24 BIONEEDS INDIA PRIVATE LIMITED 199
TABLE 152 BIONEEDS INDIA PRIVATE LIMITED: BUSINESS OVERVIEW 199
11.25 VIPRAGEN BIOSCIENCES 200
TABLE 153 VIPRAGEN BIOSCIENCES: BUSINESS OVERVIEW 200
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 201
12.1 DISCUSSION GUIDE 201
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 204
12.3 AVAILABLE CUSTOMIZATIONS 206
12.4 RELATED REPORTS 207
12.5 AUTHOR DETAILS 208

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（薬学的薬物）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22　10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.